CClinicalTrials.gg
CompletedNCT03081663Updated Apr 6, 2023

Quadriceps Sparing Versus Standard Total Knee Arthroplasty

An interventional study of Quads-Sparing Approach and Medial Para-Patellar Approach in Knee Osteoarthritis and Knee Arthroplasty, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-06.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized clinical trial comparing standard medial para-patellar total knee arthroplasty with a quadriceps sparing mid-vastus approach. Patients who are medically well and have a good support structure at home will be randomized to a standard or quadriceps sparing surgical approach stratified by type of analgesia (adductor canal block or local infiltration). We will compare patient satisfaction and costs from the perspective of the Ministry of Health, the institution, society and the patient.

Read the detailed description

Over the past 20 years the length of stay in hospital after total knee replacements has decreased from 9 days to 3 days in Canada and in just the last 10 years the mean length of stay has decreased by half from 6 to 3 days. In order to discharge patients quicker from hospital it's been theorized that less invasive techniques and better, longer lasting anaesthesia are required.

The less invasive quadriceps sparing mid-vastus approach for TKA has been compared to the standard medial para-patellar technique in many studies. Meta-analyses that have looked at studies comparing these approaches have shown some early advantages for quadriceps sparing early post-surgery, but no differences between groups later on and no difference in complications. Early advantages of the mid-vastus approach could potentially allow for earlier and safer discharge from hospital.

Adductor canal block (ACB) and local infiltration analgesia (LIA) form the mainstay of opioid sparing multimodal analgesia for TKA. The nerves of the adductor canal innervate the superficial and deep tissues of the anterior and medial aspects of the knee. ACB has been shown to provide equivalent analgesia while maintaining quadriceps power compared to femoral nerve block (FNB). LIA involves infiltrating the soft tissues of the posterior, lateral and medial aspects of the knee with local anesthetics, ketorolac and morphine. Due to their minimal impact on motor function, ACB and LIA are suitable for fast track TKA.

In combination, quadriceps sparing mid-vastus TKA with ACB may allow patients to be discharged from hospital quicker when compared with standard medial para-patellar TKA with LIA. With our study we aim to investigate whether a quadriceps sparing TKA can provide cost savings without changing complication rates when compared to the current standard of care.

02

Conditions studied

  • Knee Osteoarthritis
  • Knee Arthroplasty

Keywords

  • total knee arthroplasty
  • quadriceps sparing mid-vastus
  • medial para-patellar
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 83 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 309 studies on the registry; 126 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients requiring primary total knee replacement
  • patients willing and able to comply with follow-up requirements and self-evaluations
  • patients willing to sign an IRB approved informed consent form
  • English fluency (printed instructions are provided in English only)
  • varus arthropathy
  • osteoarthritis
  • ASA less than or equal to 3
  • home/cell phone access
  • adult to accompany patient home post-operatively and to stay with patient for a minimum period of 1-2 days

Exclusion criteria

Exclusion Criteria:

  • patients with inflammatory arthritis
  • patients with a BMI greater than 40 or less than 18
  • patients who are skeletally immature
  • patient with an active infection or suspected latent infection in or about the joint
  • bone stock that is inadequate for support or fixation of the prosthesis
  • hardware precluding intramedullary instrumentation
  • prior osteotomies of the femur or tibia
  • patients living greater than 1.5 hours from the hospital
  • patients without access to caregivers, or unable to go to their home after surgery
  • cognitive or neuromotor conditions
  • patient has significant pain management issues
  • patient/family history of anaesthesia related complications (e.g. malignant hypothermia, pseudocholinesterase deficiency, airway difficulties, obstructive sleep apnea)
  • significant psycho/social issues that would prevent the patient from managing at home safely
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Quads-Sparing Approach with Tourniquet

    Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.

    Procedure: Quads-Sparing Approach

  • Active comparator
    Medial Para-Patellar with Tourniquet

    Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.

    Procedure: Medial Para-Patellar Approach

  • Active comparator
    Quads-Sparing Approach w/o Tourniquet

    Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.

    Procedure: Quads-Sparing Approach

  • Active comparator
    Medial Para-Patellar w/o Tourniquet

    Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.

    Procedure: Medial Para-Patellar Approach

Interventions

  • ProcedureQuads-Sparing Approach

    Quadriceps-sparing mid-vastus approach for total knee arthroplasty

    Also known as: quads-sparing

  • ProcedureMedial Para-Patellar Approach

    Medial para-patellar approach for total knee arthroplasty

    Also known as: standard

06

What researchers measure

Primary outcomes

  1. Indirect and Direct Costs of Treatment

    ER visits, clinician visits, caregiver lost productivity, tests, etc.

    Time frame: 1 year

Secondary outcomes

  1. Pain Numeric Rating Scale

    Pain

    Time frame: 1 year

  2. Short Form - 12 (SF-12)

    Quality of Life

    Time frame: 1 year

  3. Western Ontario McMaster Osteoarthritis Index (WOMAC)

    Functional Outcome

    Time frame: 1 year

  4. Knee Society Score (KSS)

    Functional Outcome

    Time frame: 1 year

  5. EuroQol-5D (EQ-5D)

    Quality of Life

    Time frame: 1 year

  6. Timed Up and Go Test

    Function

    Time frame: 1 year

  7. Adverse events

    Falls, wound problems, pulmonary embolism, deep vein thrombosis, infection, etc.

    Time frame: 1 year

  8. Caregiver Assistance Scale

    Caregiver Confidence

    Time frame: 6 weeks

  9. Caregiver Strain Index

    Caregiver Strain

    Time frame: 6 weeks

  10. Patient Satisfaction Questionnaire

    Patient satisfaction

    Time frame: 2 weeks

07

Study locations

1 site
  • London Health Sciences Centre
    London, Ontario N6A5A5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03081663
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Responsible party
Brent Lanting (Orthopaedic Surgeon, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Mar 16, 2017
Start date
Jul 11, 2017
Primary completion
Dec 16, 2021
Completion
Dec 16, 2021
Last update
Apr 6, 2023

Study contacts

Brent A Lanting, MD
principal investigator · London Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion